Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

Exclusion Criteria

• •Received a non-FDA approved investigational agent within the last 4 weeks.
• •Previous cancer therapies (chemotherapy, hormonal therapy, monoclonal antibodies or radiation therapy) within the last 3 weeks, 8 weeks for fully human or humanized monoclonal antibodies
• •Infection requiring antibiotics or hospitalization within the last 2 weeks
• •HIV, Hepatitis-B, Hepatitis-C
• •Pregnant or breast-feeding women
• •Major surgery within the last 4 weeks
• •History of other cancers within the past 5 years